ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEXT STORY
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
PREV STORY
Verrica Announces Proposed Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Announces Participation in Three Investor Conferences

ROCKVILLE, MD, Oct. 22, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage ...

author_avatar
NASDAQ Market News

Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven ...

author_avatar
NASDAQ Market News

Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York

MALVERN, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, ...

author_avatar
NASDAQ Market News